Follow Us:
Login
Register
Logout
My Profile
My Courses
Courses
Specialties
Hematology/Oncology
Primary Care
Neurology
Cardiology
Psychiatric Medicine
Asthma & Allergies
Events
COVID-19
Home
» Recent Developments in Immuno-oncology: Biomarkers, Pan-tumor Studies, Novel Treatment Combinations, and the Management of Adverse Events
Recent Developments in Immuno-oncology: Biomarkers, Pan-tumor Studies, Novel Treatment Combinations, and the Management of Adverse Events
CME: 1.0
June 22, 2020
No Comments
Email
/
Print
/
Reprints
/
|
More
/
Text Size+
Larger
Smaller
[X]
Related Articles
Recent Developments in Immuno-oncology: Biomarkers, Pan-tumor Studies, Novel Treatment Combinations, and the Management of Adverse Events Track 2: Biomarkers for Immunotherapies Across Tumor Type
Recent Developments in Immuno-oncology: Biomarkers, Pan-tumor Studies, Novel Treatment Combinations, and the Management of Adverse Events
This case-based enduring activity will cover the diagnosis, treatment, and management of patients with cancer who are treated or eligible for treatment with immunotherapy.
Source:
https://learning.freecme.com/a/34993PAU2rbF
Post a comment to this article
Name
*
E-mail
(will not be displayed)
*
Subject
Comment
*
Report Abusive Comment
Thank you for helping us to improve our forums. Is this comment offensive? Please tell us why.